Evidence map›Paper›PMID 42052901›Full record

Observational studyFuture oncology (London, England)2026

Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.

Neal D Shore, Nasreen Khan, Rana R McKay, Niculae Constantinovici, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Zdravko Vassilev, Daniel E Spratt

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Neal D ShoreAtlantic Urology Clinics, START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Nasreen KhanBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Rana R McKayDivision of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA.
Niculae ConstantinoviciBayer Consumer Care AG, Basel, Switzerland.
Guifang ChenBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Vlasta HlebecBayer Consumer Care AG, Basel, Switzerland.
Shankar SrinivasanBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Zdravko VassilevBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups. PATIENTS AND

methodsRetrospective observational study of patients with non-metastatic prostate cancer (PC) (

resultsBCR occurred in 19.7% of patients after RP and 8.8% after RT. Among high-risk BCR patients (

conclusionsPSA and PSA-DT are key predictors of BCR. Outcomes are worse among high-risk BCR patients with short PSA-DT.

Indexed as

Neoplasm Recurrence, LocalProstate-Specific AntigenProstatic NeoplasmsAgedHumansMaleMiddle AgedProstatectomyRetrospective StudiesTreatment OutcomeProstate-Specific Antigenbiochemical recurrencenon-metastatic prostate cancerprostate-specific antigenReal-worldretrospective

Identifiers

PMID42052901
PMCPMC13155023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.